Core Viewpoint - SIGA Technologies, Inc. has reported its financial results for Q1 2025, indicating a decline in product sales and total revenues compared to the same period in 2024, while also highlighting significant future sales expectations from government orders and international sales [2][3]. Financial Performance - Product sales for Q1 2025 were $5.8 million, down from $23.9 million in Q1 2024, representing a decrease of approximately 75.8% [3]. - Total revenues decreased to $7.0 million in Q1 2025 from $25.4 million in Q1 2024, a decline of about 72.5% [3]. - The company reported an operating loss of $2.3 million for Q1 2025, compared to an operating income of $11.3 million in Q1 2024 [3]. - Net loss for Q1 2025 was $0.4 million, a significant drop from a net income of $10.3 million in Q1 2024 [3]. Business and Operational Activity - SIGA has outstanding Strategic National Stockpile orders totaling $94 million as of March 31, 2025, with expectations to deliver $70 million of these orders by the end of Q3 2025 [2][8]. - The company received a $26 million procurement order for IV TPOXX from the U.S. Government in March 2025 [9]. - In April 2025, SIGA delivered approximately $53 million of oral TPOXX and $9 million of IV TPOXX to the Strategic National Stockpile [9]. - TPOXX received regulatory approval in Japan for the treatment of smallpox and related diseases, marking a significant milestone for the company [9]. Capital Management - A special cash dividend of $0.60 per share was declared on April 8, 2025, to be paid on May 15, 2025 [6]. Assets and Liabilities - As of March 31, 2025, total assets were reported at $247.1 million, slightly up from $244.3 million as of December 31, 2024 [15][16]. - Current liabilities increased to $27.8 million from $25.3 million in the previous quarter [16]. Shareholder Information - The weighted average shares outstanding for basic and diluted calculations were 71.4 million for Q1 2025 [17].